philipn / COVID-19 therapeutics 28d47722f1b0a8696b1b60981f279e5322e47ba3

Create Draft
Linking ACE2 for COVID-19
Review changes View this version of the page
You can also use the and keys
Deletions are marked like this Additions are marked like this

This page details potential COVID-19 theraputics. Substances listed here are not necessarily effective. Potential medications are detailed because they are on trial for use in COVID-19 or have been described as a potential treatment in an academic paper.

Theraputic is another word for a treatment. Theraputics are drugs that can be given to someone once (or shortly before) they have been infected by SARS-CoV-2. Vaccines, in contrast, are given before an infection happens and protect against the development of disease.

Anti-virals

Potential neutralizing strategies as described in "Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China". Photo CC-BY Robert L. Kruse.
  • Convalescent plasma
  • Remdesivir
  • GS-441524
  • MK-4482 (formerly known as EIDD-2801)
  • Favipiravir
  • Hydroxychloroquine and Chloroquine
  • Dipyridamole
  • Niclosamide
  • Nitazoxanide
  • Doxycycyline
  • Ciclesonide
  • Interferons
  • Camostat mesylate
  • Indomethacin
  • Bromhexine
  • Galidesivir
  • Monoclonal Antibodies
  • Amodiaquine
  • Soluable ACE2 / ACE2-fc

Host response / anti-inflammatory

See also

This page details potential COVID-19 theraputics. Substances listed here are not necessarily effective. Potential medications are detailed because they are on trial for use in COVID-19 or have been described as a potential treatment in an academic paper.

Theraputic is another word for a treatment. Theraputics are drugs that can be given to someone once (or shortly before) they have been infected by SARS-CoV-2. Vaccines, in contrast, are given before an infection happens and protect against the development of disease.

Anti-virals

Potential neutralizing strategies as described in "Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China". Photo CC-BY Robert L. Kruse.
  • Convalescent plasma
  • Remdesivir
  • GS-441524
  • MK-4482 (formerly known as EIDD-2801)
  • Favipiravir
  • Hydroxychloroquine and Chloroquine
  • Dipyridamole
  • Niclosamide
  • Nitazoxanide
  • Doxycycyline
  • Ciclesonide
  • Interferons
  • Camostat mesylate
  • Indomethacin
  • Bromhexine
  • Galidesivir
  • Monoclonal Antibodies
  • Amodiaquine
  • Soluable ACE2 / ACE2-fc

Host response / anti-inflammatory

See also
Create Draft
Contributed by
Except where otherwise noted, text content is licensed under a Creative Commons Attribution-ShareAlike License. See copyright information.